MedTrace Logo

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39603

Last updated 2022-11-02

No results posted yet for this study

Summary

The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant options, and the impact of venous thromboembolism on patient-defined outcomes, such as quality-of-life, symptom burden, and treatment satisfaction. This information is crucial to helping clinicians and patients choose between various treatment options for venous thromboembolism in order to achieve the best possible balance between the risks, benefits, and impact on health.

Conditions

  • Venous Thromboembolism
  • Anticoagulants and Bleeding Disorders

Interventions

DRUG

Oral Anticoagulant

Oral anticoagulants used to treat or prevent venous thromboembolism

Sponsors & Collaborators

Principal Investigators

  • Margaret C. Fang, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2019-12-31
Completion
2022-06-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03292666 on ClinicalTrials.gov